PRINCETON, N.J., and OXFORD, England, April 6, 2011 /PRNewswire/
— BioWa, Inc. (BioWa) and Oxford BioTherapeutics Ltd (OBT) today
announced that they have entered into a license agreement to
provide OBT with access to BioWa’s patented POTELLIGENT®
Technology platform for the development of antibody dependent
cellular cytotoxicity (ADCC) enhanced antibodies.
OBT intends to use POTELLIGENT® Technology to develop,
manufacture and commercialize selected ADCC programs from its
pipeline of preclinical antibodies for oncology which it has built
based upon novel targets identified using its OGAP® proteomic
In return for the license, OBT will pay to BioWa undisclosed
license fees, development and commercialization milestones and
royalties on sales of any products that it commercializes.
“We are delighted to have access to BioWa’s POTELLIGENT®
Technology as part of our technology access portfolio as we build a
pipeline of first-in-class therapeutic antibodies for cancer,” said
Christian Rohlff, CEO of OBT. “Our strategy is to combine
novel proprietary oncology targets with world-leading antibody
technologies, such as POTELLIGENT® Technology, to develop
highly efficacious new cancer drugs for patients with few treatment
“The OBT cancer specific antibody portfolio has matured to an
advanced stage where coupling to BioWa’s POTELLIGENT®
Technology enhances already promising anticancer agents and further
enables our clinical development pipeline,” commented OBT’s Senior
Vice President of Oncology, Jon Terrett.
“We are excited to expand our set of small company arrangements
with OBT. In large part, our decision to partner with OBT was
driven by our interest in novel therapeutic antibody targets
identified through the OGAP® proteomic database,” said Yasunori
Yamaguchi, President and CEO of BioWa.
About POTELLIGENT® Technology